239 related articles for article (PubMed ID: 23557017)
41. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
42. Driving drug discovery and patient therapy via the encapsulation and fusion of knowledge.
Collins MA; Shaw I; Billington DC
Drug Des Discov; 1999 Nov; 16(3):181-94. PubMed ID: 10624564
[TBL] [Abstract][Full Text] [Related]
43. A vision of the pharmaceutical industry.
Muñio S
Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():5-9. PubMed ID: 9800720
[TBL] [Abstract][Full Text] [Related]
44. Pharmaceutical industry overview: optimal drug therapy.
Blake P
Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380
[TBL] [Abstract][Full Text] [Related]
45. Discontinued drugs in 2010: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
[TBL] [Abstract][Full Text] [Related]
46. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
47. Biotech acquisitions by big pharma: why and what is next.
Malik NN
Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
[TBL] [Abstract][Full Text] [Related]
48. The changing environment for technological innovation in health care.
Goodman CS; Gelijns AC
Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
[TBL] [Abstract][Full Text] [Related]
49. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
50. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
51. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
52. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
53. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
54. Profit pools: a fresh look at strategy.
Gadiesh O; Gilbert JL
Harv Bus Rev; 1998; 76(3):139-47. PubMed ID: 10179649
[TBL] [Abstract][Full Text] [Related]
55. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift.
Sams-Dodd F
Drug Discov Today; 2013 Mar; 18(5-6):211-7. PubMed ID: 23131208
[TBL] [Abstract][Full Text] [Related]
56. Drug patent expirations and the speed of generic entry.
Bae JP
Health Serv Res; 1997 Apr; 32(1):87-101. PubMed ID: 9108806
[TBL] [Abstract][Full Text] [Related]
57. Patent indicators: a window to pharmaceutical market success.
Guo Y; Hu Y; Zheng M; Wang Y
Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
[TBL] [Abstract][Full Text] [Related]
58. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
59. The value of drug repositioning in the current pharmaceutical market.
Tobinick EL
Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
[TBL] [Abstract][Full Text] [Related]
60. A few specialty drug prices fall--all generics.
Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
